Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tempol for Prevention of Mucositis in Head and Neck Cancer
NCT03480971Phase 2Recruiting
- Sponsor
- Matrix Biomed, Inc.
- Start
- May 2019
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tempol in mucositis, nephrotoxicity, ototoxicity, sponsored by Matrix Biomed, Inc.. Started May 2019; status: recruiting.
02
Drugs
tempol
03
Conditions
mucositisnephrotoxicityototoxicity
Beyond the preview
Go deeper on NCT03480971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480971.